Search hospitals

>

Massachusetts

>

Springfield

Baystate Medical Center

Claim this profile

Springfield, Massachusetts 01199

Global Leader in HIV Infection

Global Leader in Human Immunodeficiency Virus Infection

Conducts research for Ovarian Cancer

Conducts research for Lung Cancer

Conducts research for Breast Cancer

446 reported clinical trials

25 medical researchers

Photo of Baystate Medical Center in SpringfieldPhoto of Baystate Medical Center in SpringfieldPhoto of Baystate Medical Center in Springfield

Summary

Baystate Medical Center is a medical facility located in Springfield, Massachusetts. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Ovarian Cancer, Lung Cancer, Breast Cancer and other specialties. Baystate Medical Center is involved with conducting 446 clinical trials across 732 conditions. There are 25 research doctors associated with this hospital, such as Tashanna Myers, John C. McCann, Joanna G. Luty, and Amir Lotfi, MD.

Top PIs

Clinical Trials running at Baystate Medical Center

Ovarian Cancer

Lung Cancer

Stroke

Cancer

Breast Cancer

Testicular cancer

Endometrial Cancer

Atrial Fibrillation

Non-Small Cell Lung Cancer

Uterine Cancer

Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Baystate Medical Center?

Where is Baystate Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Baystate Medical Center accept?

What awards or recognition has Baystate Medical Center received?